A new proposal in JAMA Internal Medicine suggests that the FDA should create an approval pathway for medical AI tools that parallels how physicians are trained and licensed.
Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...
Radiopharmaceutical therapy (RPT) offers molecular-targeted treatment strategies and presents an ideal model for advancing ...
The cell and gene therapy market is at a pivotal point, with a surge in approvals and a maturing pipeline. While oncology ...
Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...
Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...
Long COVID has emerged as a significant health concern following the SARS-CoV-2 pandemic, affecting millions worldwide. This condition is characterized by prolonged symptoms that persist for weeks or ...
PsyPost on MSN
Scientists trace a pathway from gut microorganisms to neuropsychiatric disorders via fat molecules
New genetic research has identified a direct causal chain connecting the microorganisms in the human digestive tract to the ...
The Global Vagus Nerve Stimulation Market Size projected to grow at a CAGR of 10.50% from 2024 to 2031, according to a new ...
True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...
EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the ...
Do No Harm alleges Utah Department of Health and Human Services "systematic review" misleads on transgender outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback